Hitting KRAS G12D without the gut punch: Can immunotherapy make it last?

Combining HRS-4642 with adebrelimab yields a 43% response rate in previously treated metastatic pancreatic cancer without gastrointestinal toxicity.

• Why it matters: Pancreatic cancer patients have limited treatment options, and current KRAS inhibitors often cause gastrointestinal side effects, limiting their use.
• What they did: Shi et al. conducted an early-phase study of an intravenous, allele-specific KRAS G12D inhibitor combined with a PD-L1 inhibitor in patients with metastatic pancreatic cancer, observing safety and response.
• The result: The combination was safe, well tolerated, and achieved a 43% response rate, suggesting a promising therapeutic approach that spares patients from common gastrointestinal toxicity.